CA2142314C - Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol - Google Patents

Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Info

Publication number
CA2142314C
CA2142314C CA002142314A CA2142314A CA2142314C CA 2142314 C CA2142314 C CA 2142314C CA 002142314 A CA002142314 A CA 002142314A CA 2142314 A CA2142314 A CA 2142314A CA 2142314 C CA2142314 C CA 2142314C
Authority
CA
Canada
Prior art keywords
hmb
cholesterol
calcium salt
ldl
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002142314A
Other languages
English (en)
French (fr)
Other versions
CA2142314A1 (en
Inventor
Steven L. Nissen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iowa State University Research Foundation Inc ISURF
Original Assignee
Iowa State University Research Foundation Inc ISURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25484425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2142314(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iowa State University Research Foundation Inc ISURF filed Critical Iowa State University Research Foundation Inc ISURF
Publication of CA2142314A1 publication Critical patent/CA2142314A1/en
Application granted granted Critical
Publication of CA2142314C publication Critical patent/CA2142314C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002142314A 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol Expired - Fee Related CA2142314C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94640492A 1992-09-16 1992-09-16
US946,404 1992-09-16
PCT/US1993/008695 WO1994006417A1 (en) 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Publications (2)

Publication Number Publication Date
CA2142314A1 CA2142314A1 (en) 1994-03-31
CA2142314C true CA2142314C (en) 1999-06-01

Family

ID=25484425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002142314A Expired - Fee Related CA2142314C (en) 1992-09-16 1993-09-15 Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol

Country Status (12)

Country Link
US (1) US5360613A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0660706B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3148243B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU673002B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9307035A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2142314C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69327468T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2142353T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI951218A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO951000L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ256300A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994006417A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2000043017A1 (en) * 1999-01-21 2000-07-27 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
PL367221A1 (en) * 2001-05-18 2005-02-21 Lonza Ag Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
EP1750527A1 (en) * 2004-03-11 2007-02-14 Wiley Organics, Inc. Compositions and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2007056176A2 (en) * 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
EP1968564B1 (en) 2005-12-19 2015-09-16 Abbott Laboratories Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
HUE039841T2 (hu) * 2008-12-09 2019-02-28 Metabolic Tech Inc Táplálkozási beavatkozás izomfunkció és erõ növeléséhez
US8538727B2 (en) * 2009-07-21 2013-09-17 George S. Cembrowski Method and apparatus for calibration and testing of scientific measurement equipment
US11042605B2 (en) 2009-07-21 2021-06-22 Ccqcc Corp. Method and apparatus for calibration and testing of scientific measurement equipment
JP6076741B2 (ja) 2010-01-29 2017-02-08 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ 無菌包装されているｈｍｂを含む栄養液
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
TWI580363B (zh) 2010-01-29 2017-05-01 亞培公司 包含鈣ｈｍｂ的營養乳劑
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
WO2013012760A1 (en) * 2011-07-15 2013-01-24 Numeta Sciences, Inc. Compositions and methods for modulating metabolic pathways
BR112014003434A2 (pt) * 2011-08-15 2017-03-01 Abbott Lab processo para produção de hmb e seus sais
WO2013067485A1 (en) 2011-11-03 2013-05-10 University Of Florida Research Foundation, Inc. Nutritional supplement for weight management
WO2012140276A2 (en) * 2011-11-17 2012-10-18 Lonza Ltd Process for the preparation of 3-hydroxy-3-methylbutyric acid or its calcium salts
FI3733171T3 (fi) 2012-09-10 2024-01-24 Metabolic Tech Llc Koostumuksia sisältäen hmb:tä ja atp:tä sekä niiden käyttö
CA2944004C (en) 2014-03-27 2023-08-15 Roland W. Winterfield Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
HUE066456T2 (hu) 2015-09-16 2024-08-28 Metabolic Tech Llc A béta-hidroxi-béta-metil-butirát (HMB) kompozíciói és felhasználási módszerei a lágyrész trauma utáni helyreállítás fokozására
JP6875288B2 (ja) * 2015-11-19 2021-05-19 協和発酵バイオ株式会社 ３−ヒドロキシイソ吉草酸の一価カチオン塩の結晶および該結晶の製造方法
AU2017210335A1 (en) 2016-01-21 2018-08-02 Metabolic Technololgies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy
CA3028608A1 (en) 2016-06-24 2017-12-28 Otsuka Pharmaceutical Factory, Inc. Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof
JP7583523B2 (ja) 2016-10-21 2024-11-14 メタボリック・テクノロジーズ，インコーポレーテッド β－ヒドロキシ－β－メチルブチレート（ＨＭＢ）およびプロバイオティックを使用する組成物および方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3629449A (en) * 1968-04-22 1971-12-21 Majid Siddiqi Process of combatting hypercholesterolemia
US4764531A (en) * 1986-03-11 1988-08-16 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to laying chickens
US4760090A (en) * 1986-03-11 1988-07-26 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to cattle and sheep
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals

Also Published As

Publication number Publication date
WO1994006417A1 (en) 1994-03-31
FI951218L (fi) 1995-03-15
JPH08501777A (ja) 1996-02-27
FI951218A0 (fi) 1995-03-15
CA2142314A1 (en) 1994-03-31
NO951000D0 (no) 1995-03-15
JP3148243B2 (ja) 2001-03-19
AU4922593A (en) 1994-04-12
US5360613A (en) 1994-11-01
ES2142353T3 (es) 2000-04-16
NZ256300A (en) 1997-06-24
DE69327468D1 (de) 2000-02-03
EP0660706B1 (en) 1999-12-29
BR9307035A (pt) 1999-06-29
FI951218A7 (fi) 1995-03-15
DE69327468T2 (de) 2000-05-11
NO951000L (no) 1995-03-15
AU673002B2 (en) 1996-10-24
EP0660706A1 (en) 1995-07-05
EP0660706A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-07-26

Similar Documents

Publication Publication Date Title
CA2142314C (en) Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol
AU664511B2 (en) Method of promoting nitrogen retention in humans
RU2221558C2 (ru) Новые аналоги жирных кислот для лечения диабета
NISSEN et al. The effect of β-hydroxy-β-methylbutyrate on growth, mortality, and carcass qualities of broiler chickens
JPH0662758A (ja) バイオマスの利用
JPH04230624A (ja) 犬の加齢による認知機能障害を治療する方法
EA025256B1 (ru) Композиция, подходящая для лечения нарушений липидного обмена
JP4447913B2 (ja) オステオポローシス治療のための組成物の製造のためのグルタミン酸塩、グルタミン酸塩誘導体又はグルタミン酸塩代謝物、グルタミン酸塩アナログ或いはそれらの混合物の使用
JP3873097B2 (ja) 抗肥満剤及び脂質代謝改善剤
US5240962A (en) Antiobesity and fat-reducing agents
Pamukcu et al. Effects of the coadministration of thiamine on the incidence of urinary bladder carcinomas in rats fed bracken fern
US5552442A (en) Therapeutic applications of clenbuterol
Hrab et al. Prevention of fluvastatin‐induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation
EP0662324A1 (en) Use of beta-adrenergic agonists for treating loss of function of striated muscles
US4937077A (en) Method for improving feed conversion of meat-producing animals by oral administration of 2-deoxy-D-hexose
KR100304312B1 (ko) 아연이보충된전립선추출물
US5530029A (en) Therapeutic applications of clenbuterol
JPS6299323A (ja) 高脂血症剤
JP3858055B2 (ja) 抗肥満剤及び脂質代謝改善剤
WO2002003813A1 (en) Use of dammarane-type triterpenoid saponins
Folley et al. Reproduction and lactation in the rat on highly purified diets
Sebrell Fatty Degeneration of the Liver and Kidneys in the Dog Apparently Associated with Diet: A Preliminary Note
US8415299B2 (en) Methods for improved avian performance
KR20080094466A (ko) 대사증후군 치료용 약제 조성물
Shaklee Research on cholesterol in poultry and eggs in the United States

Legal Events

Date Code Title Description
EEER Examination request
MKLC Lapsed (correction)
MKLA Lapsed